Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.62 AUD | +0.97% | -1.01% | +54.96% |
May. 27 | Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA | MT |
May. 27 | Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent | CI |
Sales 2024 * | 744M 495M | Sales 2025 * | 940M 626M | Capitalization | 5.17B 3.44B |
---|---|---|---|---|---|
Net income 2024 * | 54M 35.94M | Net income 2025 * | 104M 69.21M | EV / Sales 2024 * | 6.8 x |
Net cash position 2024 * | 108M 71.66M | Net cash position 2025 * | 200M 133M | EV / Sales 2025 * | 5.28 x |
P/E ratio 2024 * |
92.8
x | P/E ratio 2025 * |
48.5
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.38% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +0.97% | ||
1 week | -1.01% | ||
Current month | +3.79% | ||
1 month | +0.71% | ||
3 months | +25.56% | ||
6 months | +61.53% | ||
Current year | +54.96% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | 49 | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | 49 | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | 64 | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 14 M€ | -4.84% | ||
0.04% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 15.62 | +0.97% | 773 761 |
24-05-28 | 15.47 | -2.64% | 725,007 |
24-05-27 | 15.89 | +2.71% | 1,016,542 |
24-05-24 | 15.47 | -0.77% | 1,395,396 |
24-05-23 | 15.59 | -1.20% | 2,006,435 |
Delayed Quote Australian S.E., May 29, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.96% | 3.44B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- TLX Stock